Improving Adherence to Lipid-Lowering Treatments
Failed to add items
Add to basket failed.
Add to Wish List failed.
Remove from Wish List failed.
Follow podcast failed
Unfollow podcast failed
Improving Adherence to Lipid-Lowering Treatments
-
Narrated by:
-
By:
About this listen
Secondary prevention of atherosclerotic cardiovascular disease (ASCVD) often requires the use of lifelong therapies. How can healthcare providers promote adherence to secondary prevention interventions to help high-risk patients achieve their lipid goals?
Our host, Dr. Liam Brunham, takes a deeper look into this topic with Dr. Tara Sedlak, a cardiologist at Vancouver General Hospital and BC Women's Hospital, and Director of the Leslie Diamond Women's Heart Health Clinic.
Despite the availability of lipid-lowering therapies that reduce the risk of morbidity and mortality, many patients with established ASCVD are not achieving guideline-recommended lipid targets. This episode takes a closer look at some of the factors contributing to this care gap, with a focus on the reasons why patients may be discontinuing their medications. Our experts discuss practical strategies to optimize adherence and secondary prevention for improved outcomes. In addition, they also explore the various ways in which treatments can be personalized to individual patient needs, and how best to support and empower patients in their journey toward optimal lipid management.
Don’t miss the conversation!
The views and opinions expressed in this episode are those of the speakers and do not necessarily reflect the views or positions of any entities they represent.
Declaration of conflict of interest:
Dr. Brunham:
- Direct financial relationship including receipt of honoraria: Sanofi, Amgen, HLS, Pfizer, Ultragenyx, Novartis, Novo Nordisk. Membership on advisory boards or speaker’s bureau: Sanofi, Amgen, HLS, Pfizer, Ultragenyx, Novartis, Novo Nordisk. Funded grants, research, or clinical trials: Amgen, Novartis, Ionis.
Dr. Sedlak:
- Direct financial relationship including receipt of honoraria: Amgen, Novo Nordisk, Sanofi, KYE Pharmaceuticals, Pendopharm, Boehringer Ingelheim, Eli Lilly, Bayer, Novartis, Pfizer. Membership on advisory boards or speaker’s bureau: Amgen, Novo Nordisk, KYE Pharmaceuticals, Boehringer Ingelheim, Lilly.
MAT-CA-2301816 App Dec 2023